.@JohnLFlavin was on Bloomberg TV to discuss the recent bull run in the biotech market along with how alternative funding sources like the state of New Jersey, the Michael J. Foundation, and CPRIT are helping fund early-stage startups. Take a look! https://t.co/cUqYnleBYp
Support shouldn’t stop once a visit or group ends. DBSA’s newsletter keeps you connected with peer stories, practical education, and updates on programs and advocacy. It’s written for real life and meant to be shared with anyone who cares about mental health.
#MentalHealth
Today on World Mental Health Day, we're proud to announce our $2.6M Fast-Track award from NIA to further develop and use our smartphone app, Skye to better understand "brain fog" during the perimenopausal transition working with Dr. Pauline Maki at @uiccom!
Impressive results for a new app to support people with schizophrenia, given the study features a rigorous digital control group, from @Boehringer. Disclosure - I am a clinical advisor/ excited to see such advances in digital health https://t.co/yGygdQGcp3
Check out our recent work demonstrating that the scalp-based Beam/F3 method is a reliable way to target the dLPFC in #TMS for depression! We learn more by integrating personalized E-field models… 👀
With @NoahSPhilipMD, @LMWilliams_PhD, and others.
👉 https://t.co/iIhjLJS5Gv
When we founded atai Life Sciences in 2018, mental health drug development was an afterthought for Big Pharma. Challenges such as subjective clinical endpoints, complex biology, and high failure rates pushed many pharma away. Meanwhile, patient demand skyrocketed, leaving a massive innovation gap and patients behind.
Over the last two years, the tide is fortunately turning. Bristol Myers Squibb’s $14B acquisition of Karuna Therapeutics and Johnson & Johnson $15B deal for Intra-Cellular Therapies signal a resurgence of interest. And in addition, private investments in biotechs active in mental health drug development have significantly increased (see graph in article).
It's encouraging to see the @WSJ and @david_wainer covering Psychedelics as a key innovation catalyst in mental health that is gaining traction. Given the number of Phase 2 and Phase 3 clinical trial readouts this year, the next 12 months will be super interesting to watch.
The past decade has proven that breakthroughs come from those willing to challenge the status quo. Great to see that investors and big pharma players are paying more and more attention to the huge unmet patient needs in mental health and making moves to again allocate significant amounts of capital to neuroscience given the progress made over the last years.
See here for the full article: https://t.co/MlQZgJEejd
#mentalhealth #neurosciecne #psychedelics #drugdevelopment #BigPharma
Our hall of inventions at the #CBCSummit2024 is really buzzing! We’re showcasing over 140 academic innovators from 11 universities across the Midwest to show the incredible talent coming out of our region!
Every day, over 300 million people face the struggle of depression. 1 in 3 find no relief in current treatment options. For those living with treatment-resistant depression, hope feels out of reach. We're proud to share the next video in our #OneBillionPeople series, highlighting the challenges of living with TRD. #MentalHealth
📢 A new #investment, packed Fall calendar, & exciting news! Plus: PortCo updates + a Spotlight on Olu Ajilore, co-founder of KeyWise AI, blending cross-cultural & cross-disciplinary expertise in medicine, research, & tech.
🔗https://t.co/rwTLA4w8IB
#Innovation#HealthTech
@thisisUIC researcher Pauline Maki joined actress Halle Berry on Good Morning America this morning to talk about the stages and symptoms of menopause. Watch the segment: https://t.co/ImlNUIpgiI
Technologies that I was told would revolutionize health care in my career so far:
— 2010-2012: Electronic medical records
— 2012-2017: AI
— 2017-2020: Wearables
— 2020-2023: Blockchain and telemedicine
2023 onwards: AI, take two
Congratulations to our co-founder @raeannephd for leading KeyWise AI's work on developing innovative solutions for Alzheimer's Disease and Related Dementias!
Congrats to the 6 teams competing for $250K - $1M in funding at the virtual pitch competition for the NACC/Gates Ventures AD/ADRD Digital Pilot Program! Join us in cheering on these teams May 31 at 1:00–3:30pm ET. Register today, all are welcome: https://t.co/PrxNiFM8ZK
Congrats to the 6 teams competing for $250K - $1M in funding at the virtual pitch competition for the NACC/Gates Ventures AD/ADRD Digital Pilot Program! Join us in cheering on these teams May 31 at 1:00–3:30pm ET. Register today, all are welcome: https://t.co/PrxNiFM8ZK
I am not an optimist (I'm a realist). But I wrote an optimistic post for Second Opinion about a lot of categories of health-tech that are actually doing well and why you shouldn't be a tourist.
Let me know what you think!